TG Therapeutics Reports TGR-1202 in Combo with Ibrutinib in Patients with Relapsed, Refractory CLL, MCL Showed Combo is Well Tolerated with No Grade 3/4 Transaminitis, Pneumonitis, Diarrhea, Colitis Observed
Paul Quintaro